Skip to content

Treatment Preference in Patients with NMOSD

Treatment Preference in Patients with NMOSD

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-jRCT1030230308
Enrollment
300
Registered
2023-08-25
Start date
2025-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromyelitis Optica Spectrum Disorders NMOSD

Interventions

None listed

Sponsors

Yamashita Katsuhisa
Lead Sponsor
Nishi Kazuhiko
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Subjects who meet all of the following criteria: (1)Documented diagnosis of NMOSD (2)aquaporin-4 antibody test positive (3)Patients aged 20 years or older at the time of enrollment (4)Must have sufficient understanding to conduct the research (The patient may require assistance in reading aloud, etc. due to visual disturbance.) (5)Individuals who have consented to participate in this research (6)Patients who are living in Japan at the time of enrollment (7)Individuals who have equipment/communication environment to apply for research participation online and respond to questionnaires

Exclusion criteria

Exclusion criteria: Subjects who meet any of the following criteria: (1)Patients who have difficulty in obtaining consent or conducting this research due to a lack of Japanese ability (2)Patietnts who cannot participate in the survey

Design outcomes

Primary

MeasureTime frame
Causal relationship between Subjective Adverse Event Experience and Impact on Daily Living of Patients with NMOSD

Secondary

MeasureTime frame
subjective Adverse Event Experience and Importance of Impact on Daily Living of Patients with NMOSD

Contacts

Public ContactTadashi Nagatsuka

Chugai Pharmaceutical Co., Ltd.

cma-clinicaltrial@chugai-pharm.co.jp+81-332816611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026